Cetrelimab

Summary

Cetrelimab (CHEMBL4298001) is a phase-3 clinical-stage antibody; indicated across 9 conditions including urothelial carcinoma and urinary bladder neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 9 conditions
• Clinical trials: 21

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298001
Name	Cetrelimab
Type	Antibody
Max phase	3

Also known as: Cetrelimab, Jnj 63723283, Jnj-63723283, JNJ-63723283, JNJ63723283, CETRELIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urothelial carcinoma	3	MONDO:0040679	EFO:0008528
urinary bladder neoplasm	3	MONDO:0004987	EFO:0000294
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
neoplasm	1	MONDO:0005070	EFO:0000616
prostate adenocarcinoma	1	MONDO:0005082	EFO:0000673
chronic hepatitis B virus infection	1	MONDO:0005366	EFO:0004239
prostate carcinoma	1	MONDO:0005159	EFO:0001663
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 21.

Phase distribution

Phase	Trials
PHASE1	8
PHASE2	7
PHASE1/PHASE2	3
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04658862	PHASE3	ACTIVE_NOT_RECRUITING	A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT05714202	PHASE3	ACTIVE_NOT_RECRUITING	A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT03357952	PHASE2/PHASE3	COMPLETED	A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT02908906	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
NCT03431350	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03473743	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
NCT04592237	PHASE2	ACTIVE_NOT_RECRUITING	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
NCT04640623	PHASE2	ACTIVE_NOT_RECRUITING	A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04919512	PHASE2	ACTIVE_NOT_RECRUITING	A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT05908734	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT06511648	PHASE2	RECRUITING	Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
NCT06534190	PHASE2	RECRUITING	CD8 PET Imaging in Metastatic Solid Tumours
NCT04926181	PHASE2	TERMINATED	Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
NCT05818683	PHASE1	RECRUITING	A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT06116786	PHASE1	RECRUITING	A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06311578	PHASE1	RECRUITING	A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
NCT07027514	PHASE1	RECRUITING	A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
NCT07525141	PHASE1	RECRUITING	A Study of JNJ-1761981 in Participants With Solid Tumors
NCT03547037	PHASE1	COMPLETED	A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
NCT03551782	PHASE1	COMPLETED	A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05242445	PHASE1	COMPLETED	A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).